Diagnosis, treatment and management of lipodystrophy: the physician perspective on the patient journey
Background Lipodystrophy syndromes are a heterogeneous group of rare, life-limiting diseases characterized by a selective loss of adipose tissue and severe metabolic complications. There is a paucity of information describing the experiences and challenges faced by physicians who have seen and treat...
Uloženo v:
| Vydáno v: | Orphanet journal of rare diseases Ročník 19; číslo 1; s. 263 - 11 |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
London
BioMed Central
11.07.2024
BioMed Central Ltd BMC |
| Témata: | |
| ISSN: | 1750-1172, 1750-1172 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Background
Lipodystrophy syndromes are a heterogeneous group of rare, life-limiting diseases characterized by a selective loss of adipose tissue and severe metabolic complications. There is a paucity of information describing the experiences and challenges faced by physicians who have seen and treated patients with lipodystrophy. This study aimed to provide a better understanding of the physician’s perspective regarding the patient journey in lipodystrophy, including diagnosis, the burden of disease, and treatment approaches.
Methods
Thirty-three physicians from six countries who had seen or treated patients with lipodystrophy were interviewed using a semi-structured questionnaire. Interviews were transcribed, anonymized, and analyzed for themes and trends. Four main themes were developed: (1) the diagnostic journey in lipodystrophy including the disease features or ‘triggers’ that result in the onward referral of patients to specialist medical centers with experience in managing lipodystrophy; (2) the impact of lipodystrophy on patient quality of life (QoL); (3) the use of standard therapies and leptin replacement therapy (metreleptin) in lipodystrophy, and (4) barriers to metreleptin use.
Results
Participants reported that, due to their rarity and phenotypic heterogeneity, lipodystrophy cases are frequently unrecognized, leading to delays in diagnosis and medical intervention. Early consultation with multidisciplinary specialist medical teams was recommended for suspected lipodystrophy cases. The development and progression of metabolic complications were identified as key triggers for the referral of patients to specialist centers for follow-up care. Participants emphasized the impact of lipodystrophy on patient QoL, including effects on mental health and self-image. Although participants routinely used standard medical therapies to treat specific metabolic complications associated with lipodystrophy, it was acknowledged that metreleptin was typically required in patients with congenital generalized lipodystrophy and in some acquired generalized and partial lipodystrophy cases. A lack of experience among some participants and restrictions to access remained as barriers to metreleptin use.
Conclusions
To our knowledge, this is one of the first studies describing the qualitative experiences of physicians regarding the diagnosis and management of lipodystrophy. Other physician-centered studies may help increase the awareness of lipodystrophy among the wider medical community and support clinical approaches to this rare disease. |
|---|---|
| AbstractList | Lipodystrophy syndromes are a heterogeneous group of rare, life-limiting diseases characterized by a selective loss of adipose tissue and severe metabolic complications. There is a paucity of information describing the experiences and challenges faced by physicians who have seen and treated patients with lipodystrophy. This study aimed to provide a better understanding of the physician's perspective regarding the patient journey in lipodystrophy, including diagnosis, the burden of disease, and treatment approaches.BACKGROUNDLipodystrophy syndromes are a heterogeneous group of rare, life-limiting diseases characterized by a selective loss of adipose tissue and severe metabolic complications. There is a paucity of information describing the experiences and challenges faced by physicians who have seen and treated patients with lipodystrophy. This study aimed to provide a better understanding of the physician's perspective regarding the patient journey in lipodystrophy, including diagnosis, the burden of disease, and treatment approaches.Thirty-three physicians from six countries who had seen or treated patients with lipodystrophy were interviewed using a semi-structured questionnaire. Interviews were transcribed, anonymized, and analyzed for themes and trends. Four main themes were developed: (1) the diagnostic journey in lipodystrophy including the disease features or 'triggers' that result in the onward referral of patients to specialist medical centers with experience in managing lipodystrophy; (2) the impact of lipodystrophy on patient quality of life (QoL); (3) the use of standard therapies and leptin replacement therapy (metreleptin) in lipodystrophy, and (4) barriers to metreleptin use.METHODSThirty-three physicians from six countries who had seen or treated patients with lipodystrophy were interviewed using a semi-structured questionnaire. Interviews were transcribed, anonymized, and analyzed for themes and trends. Four main themes were developed: (1) the diagnostic journey in lipodystrophy including the disease features or 'triggers' that result in the onward referral of patients to specialist medical centers with experience in managing lipodystrophy; (2) the impact of lipodystrophy on patient quality of life (QoL); (3) the use of standard therapies and leptin replacement therapy (metreleptin) in lipodystrophy, and (4) barriers to metreleptin use.Participants reported that, due to their rarity and phenotypic heterogeneity, lipodystrophy cases are frequently unrecognized, leading to delays in diagnosis and medical intervention. Early consultation with multidisciplinary specialist medical teams was recommended for suspected lipodystrophy cases. The development and progression of metabolic complications were identified as key triggers for the referral of patients to specialist centers for follow-up care. Participants emphasized the impact of lipodystrophy on patient QoL, including effects on mental health and self-image. Although participants routinely used standard medical therapies to treat specific metabolic complications associated with lipodystrophy, it was acknowledged that metreleptin was typically required in patients with congenital generalized lipodystrophy and in some acquired generalized and partial lipodystrophy cases. A lack of experience among some participants and restrictions to access remained as barriers to metreleptin use.RESULTSParticipants reported that, due to their rarity and phenotypic heterogeneity, lipodystrophy cases are frequently unrecognized, leading to delays in diagnosis and medical intervention. Early consultation with multidisciplinary specialist medical teams was recommended for suspected lipodystrophy cases. The development and progression of metabolic complications were identified as key triggers for the referral of patients to specialist centers for follow-up care. Participants emphasized the impact of lipodystrophy on patient QoL, including effects on mental health and self-image. Although participants routinely used standard medical therapies to treat specific metabolic complications associated with lipodystrophy, it was acknowledged that metreleptin was typically required in patients with congenital generalized lipodystrophy and in some acquired generalized and partial lipodystrophy cases. A lack of experience among some participants and restrictions to access remained as barriers to metreleptin use.To our knowledge, this is one of the first studies describing the qualitative experiences of physicians regarding the diagnosis and management of lipodystrophy. Other physician-centered studies may help increase the awareness of lipodystrophy among the wider medical community and support clinical approaches to this rare disease.CONCLUSIONSTo our knowledge, this is one of the first studies describing the qualitative experiences of physicians regarding the diagnosis and management of lipodystrophy. Other physician-centered studies may help increase the awareness of lipodystrophy among the wider medical community and support clinical approaches to this rare disease. Background Lipodystrophy syndromes are a heterogeneous group of rare, life-limiting diseases characterized by a selective loss of adipose tissue and severe metabolic complications. There is a paucity of information describing the experiences and challenges faced by physicians who have seen and treated patients with lipodystrophy. This study aimed to provide a better understanding of the physician’s perspective regarding the patient journey in lipodystrophy, including diagnosis, the burden of disease, and treatment approaches. Methods Thirty-three physicians from six countries who had seen or treated patients with lipodystrophy were interviewed using a semi-structured questionnaire. Interviews were transcribed, anonymized, and analyzed for themes and trends. Four main themes were developed: (1) the diagnostic journey in lipodystrophy including the disease features or ‘triggers’ that result in the onward referral of patients to specialist medical centers with experience in managing lipodystrophy; (2) the impact of lipodystrophy on patient quality of life (QoL); (3) the use of standard therapies and leptin replacement therapy (metreleptin) in lipodystrophy, and (4) barriers to metreleptin use. Results Participants reported that, due to their rarity and phenotypic heterogeneity, lipodystrophy cases are frequently unrecognized, leading to delays in diagnosis and medical intervention. Early consultation with multidisciplinary specialist medical teams was recommended for suspected lipodystrophy cases. The development and progression of metabolic complications were identified as key triggers for the referral of patients to specialist centers for follow-up care. Participants emphasized the impact of lipodystrophy on patient QoL, including effects on mental health and self-image. Although participants routinely used standard medical therapies to treat specific metabolic complications associated with lipodystrophy, it was acknowledged that metreleptin was typically required in patients with congenital generalized lipodystrophy and in some acquired generalized and partial lipodystrophy cases. A lack of experience among some participants and restrictions to access remained as barriers to metreleptin use. Conclusions To our knowledge, this is one of the first studies describing the qualitative experiences of physicians regarding the diagnosis and management of lipodystrophy. Other physician-centered studies may help increase the awareness of lipodystrophy among the wider medical community and support clinical approaches to this rare disease. Lipodystrophy syndromes are a heterogeneous group of rare, life-limiting diseases characterized by a selective loss of adipose tissue and severe metabolic complications. There is a paucity of information describing the experiences and challenges faced by physicians who have seen and treated patients with lipodystrophy. This study aimed to provide a better understanding of the physician's perspective regarding the patient journey in lipodystrophy, including diagnosis, the burden of disease, and treatment approaches. Thirty-three physicians from six countries who had seen or treated patients with lipodystrophy were interviewed using a semi-structured questionnaire. Interviews were transcribed, anonymized, and analyzed for themes and trends. Four main themes were developed: (1) the diagnostic journey in lipodystrophy including the disease features or 'triggers' that result in the onward referral of patients to specialist medical centers with experience in managing lipodystrophy; (2) the impact of lipodystrophy on patient quality of life (QoL); (3) the use of standard therapies and leptin replacement therapy (metreleptin) in lipodystrophy, and (4) barriers to metreleptin use. To our knowledge, this is one of the first studies describing the qualitative experiences of physicians regarding the diagnosis and management of lipodystrophy. Other physician-centered studies may help increase the awareness of lipodystrophy among the wider medical community and support clinical approaches to this rare disease. Lipodystrophy syndromes are a heterogeneous group of rare, life-limiting diseases characterized by a selective loss of adipose tissue and severe metabolic complications. There is a paucity of information describing the experiences and challenges faced by physicians who have seen and treated patients with lipodystrophy. This study aimed to provide a better understanding of the physician's perspective regarding the patient journey in lipodystrophy, including diagnosis, the burden of disease, and treatment approaches. Thirty-three physicians from six countries who had seen or treated patients with lipodystrophy were interviewed using a semi-structured questionnaire. Interviews were transcribed, anonymized, and analyzed for themes and trends. Four main themes were developed: (1) the diagnostic journey in lipodystrophy including the disease features or 'triggers' that result in the onward referral of patients to specialist medical centers with experience in managing lipodystrophy; (2) the impact of lipodystrophy on patient quality of life (QoL); (3) the use of standard therapies and leptin replacement therapy (metreleptin) in lipodystrophy, and (4) barriers to metreleptin use. Participants reported that, due to their rarity and phenotypic heterogeneity, lipodystrophy cases are frequently unrecognized, leading to delays in diagnosis and medical intervention. Early consultation with multidisciplinary specialist medical teams was recommended for suspected lipodystrophy cases. The development and progression of metabolic complications were identified as key triggers for the referral of patients to specialist centers for follow-up care. Participants emphasized the impact of lipodystrophy on patient QoL, including effects on mental health and self-image. Although participants routinely used standard medical therapies to treat specific metabolic complications associated with lipodystrophy, it was acknowledged that metreleptin was typically required in patients with congenital generalized lipodystrophy and in some acquired generalized and partial lipodystrophy cases. A lack of experience among some participants and restrictions to access remained as barriers to metreleptin use. To our knowledge, this is one of the first studies describing the qualitative experiences of physicians regarding the diagnosis and management of lipodystrophy. Other physician-centered studies may help increase the awareness of lipodystrophy among the wider medical community and support clinical approaches to this rare disease. Abstract Background Lipodystrophy syndromes are a heterogeneous group of rare, life-limiting diseases characterized by a selective loss of adipose tissue and severe metabolic complications. There is a paucity of information describing the experiences and challenges faced by physicians who have seen and treated patients with lipodystrophy. This study aimed to provide a better understanding of the physician’s perspective regarding the patient journey in lipodystrophy, including diagnosis, the burden of disease, and treatment approaches. Methods Thirty-three physicians from six countries who had seen or treated patients with lipodystrophy were interviewed using a semi-structured questionnaire. Interviews were transcribed, anonymized, and analyzed for themes and trends. Four main themes were developed: (1) the diagnostic journey in lipodystrophy including the disease features or ‘triggers’ that result in the onward referral of patients to specialist medical centers with experience in managing lipodystrophy; (2) the impact of lipodystrophy on patient quality of life (QoL); (3) the use of standard therapies and leptin replacement therapy (metreleptin) in lipodystrophy, and (4) barriers to metreleptin use. Results Participants reported that, due to their rarity and phenotypic heterogeneity, lipodystrophy cases are frequently unrecognized, leading to delays in diagnosis and medical intervention. Early consultation with multidisciplinary specialist medical teams was recommended for suspected lipodystrophy cases. The development and progression of metabolic complications were identified as key triggers for the referral of patients to specialist centers for follow-up care. Participants emphasized the impact of lipodystrophy on patient QoL, including effects on mental health and self-image. Although participants routinely used standard medical therapies to treat specific metabolic complications associated with lipodystrophy, it was acknowledged that metreleptin was typically required in patients with congenital generalized lipodystrophy and in some acquired generalized and partial lipodystrophy cases. A lack of experience among some participants and restrictions to access remained as barriers to metreleptin use. Conclusions To our knowledge, this is one of the first studies describing the qualitative experiences of physicians regarding the diagnosis and management of lipodystrophy. Other physician-centered studies may help increase the awareness of lipodystrophy among the wider medical community and support clinical approaches to this rare disease. Background Lipodystrophy syndromes are a heterogeneous group of rare, life-limiting diseases characterized by a selective loss of adipose tissue and severe metabolic complications. There is a paucity of information describing the experiences and challenges faced by physicians who have seen and treated patients with lipodystrophy. This study aimed to provide a better understanding of the physician's perspective regarding the patient journey in lipodystrophy, including diagnosis, the burden of disease, and treatment approaches. Methods Thirty-three physicians from six countries who had seen or treated patients with lipodystrophy were interviewed using a semi-structured questionnaire. Interviews were transcribed, anonymized, and analyzed for themes and trends. Four main themes were developed: (1) the diagnostic journey in lipodystrophy including the disease features or 'triggers' that result in the onward referral of patients to specialist medical centers with experience in managing lipodystrophy; (2) the impact of lipodystrophy on patient quality of life (QoL); (3) the use of standard therapies and leptin replacement therapy (metreleptin) in lipodystrophy, and (4) barriers to metreleptin use. Results Participants reported that, due to their rarity and phenotypic heterogeneity, lipodystrophy cases are frequently unrecognized, leading to delays in diagnosis and medical intervention. Early consultation with multidisciplinary specialist medical teams was recommended for suspected lipodystrophy cases. The development and progression of metabolic complications were identified as key triggers for the referral of patients to specialist centers for follow-up care. Participants emphasized the impact of lipodystrophy on patient QoL, including effects on mental health and self-image. Although participants routinely used standard medical therapies to treat specific metabolic complications associated with lipodystrophy, it was acknowledged that metreleptin was typically required in patients with congenital generalized lipodystrophy and in some acquired generalized and partial lipodystrophy cases. A lack of experience among some participants and restrictions to access remained as barriers to metreleptin use. Conclusions To our knowledge, this is one of the first studies describing the qualitative experiences of physicians regarding the diagnosis and management of lipodystrophy. Other physician-centered studies may help increase the awareness of lipodystrophy among the wider medical community and support clinical approaches to this rare disease. Keywords: Diagnosis, Generalized lipodystrophy, Metreleptin, Partial lipodystrophy, Patient journey, Physician perspective, Quality of life |
| ArticleNumber | 263 |
| Audience | Academic |
| Author | Phillips, Helen Chard, Craig Patni, Nivedita Magee, David A. Akinci, Baris Araújo-Vilar, David |
| Author_xml | – sequence: 1 givenname: Nivedita orcidid: 0000-0002-5926-7784 surname: Patni fullname: Patni, Nivedita organization: Division of Pediatric Endocrinology, Department of Pediatrics, UT Southwestern Medical Center – sequence: 2 givenname: Craig surname: Chard fullname: Chard, Craig organization: Lumanity Inc – sequence: 3 givenname: David orcidid: 0000-0003-2852-7851 surname: Araújo-Vilar fullname: Araújo-Vilar, David organization: UETeM-Molecular Pathology of Rare Diseases Group, Institute of Biomedical Research (CIMUS), School of Medicine, University of Santiago de Compostela – sequence: 4 givenname: Helen surname: Phillips fullname: Phillips, Helen organization: Chiesi Global Rare Diseases – sequence: 5 givenname: David A. surname: Magee fullname: Magee, David A. email: david.magee@chiesi.com organization: Chiesi Global Rare Diseases – sequence: 6 givenname: Baris surname: Akinci fullname: Akinci, Baris organization: Depark, Dokuz Eylul University & Izmir Biomedicine and Genome Center (IBG) |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38992753$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kktv1DAUhSNURB_wB1igSGxAIsWvJE53VXlVqoQE3Vs3znXqUWIPtgcx_x7PpEUMQpUXtq-_c2T7ntPiyHmHRfGSknNKZfM-Uk4YrwgTFeFM1BV_UpzQtiYVpS07-mt9XJzGuCJE1JzIZ8Uxl13H2pqfFOaDhdH5aOO7MgWENKNLJbihnMHBiPutN-Vk137YxhT8-m57UaY7LPMiWm3BlWsMcY062Z9YerccQrI76cpvgsPt8-KpgSnii_v5rLj99PH26kt18_Xz9dXlTaXrWqaqRkDadL1g9cCFrnstDW9FoztJzWA6QKDC8B6bgTHZcAHYNj1vjAQu-56fFdeL7eBhpdbBzhC2yoNV-4IPo4KQrJ5QYdu1fWMEQC-FblAiMjYw0fZCEiNJ9nqzeK2D_7HBmNRso8ZpAod-ExUnbZe_tpUso68XdITsbJ3xKYDe4epSEkpEK3iXqfP_UHkMOFudW2tsrh8I3h4IMpPwVxphE6O6_v7tkH11f9tNP-Pw5-0Pnc6AXAAdfIwBjdI25SZlzwB2UpSoXajUEiqVQ6X2oVI7KftH-uD-qIgvophhN2JQ-yjk5j-m-g24Qt2L |
| CitedBy_id | crossref_primary_10_3389_fendo_2025_1525373 crossref_primary_10_7759_cureus_86794 crossref_primary_10_3389_fendo_2025_1597053 crossref_primary_10_3390_ijms26125669 |
| Cites_doi | 10.2147/DMSO.S130810 10.1210/clinem/dgad700 10.1007/s11892-018-1100-7 10.1056/NEJMoa012437 10.1210/clinem/dgac079 10.1210/jc.2018-02730 10.1210/jc.2017-01235 10.1210/jc.2016-2271 10.1097/01.md.0000111061.69212.59 10.1007/s11892-022-01485-w 10.1210/jc.2016-2466 10.1007/s12020-019-01862-8 10.1016/j.amsu.2017.10.024 10.1056/NEJMra025261 10.3109/10428194.2015.1040015 10.1210/jc.2018-01922 10.1111/cen.13311 10.1371/journal.pone.0197784 10.1210/jc.2015-2589 10.2217/clp.14.13 10.1016/j.ando.2022.07.674 10.1210/jc.2007-2521 10.2337/db21-1086 10.1007/s40618-018-0887-z 10.4137/CCRep.S40196 10.1007/s12020-014-0450-4 10.1210/jc.2014-4491 10.4274/jcrpe.galenos.2019.2019.0124 10.1186/s41687-022-00486-3 10.1186/s13023-023-03004-w 10.2337/diabetes.49.11.1958 10.3389/fendo.2023.1250203 10.1007/s11695-022-06329-w 10.1080/17446651.2020.1735360 10.1007/s12020-018-1589-1 10.1007/s11892-018-1099-9 10.1007/s40271-021-00511-5 10.1152/physrev.00032.2020 10.1136/bmjqs-2022-015054 10.1210/jcem.85.5.6605 10.4158/EP11229.OR 10.1111/dom.14726 10.1097/00005792-200303000-00007 10.1080/08998280.2017.11929552 10.1111/dom.15061 10.1210/jendso/bvad114.067 10.1007/s11605-016-3300-2 10.2337/dc16-0236 10.3389/fendo.2021.803189 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2024 2024. The Author(s). COPYRIGHT 2024 BioMed Central Ltd. |
| Copyright_xml | – notice: The Author(s) 2024 – notice: 2024. The Author(s). – notice: COPYRIGHT 2024 BioMed Central Ltd. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM ISR 7X8 DOA |
| DOI | 10.1186/s13023-024-03245-3 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Science MEDLINE - Academic DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1750-1172 |
| EndPage | 11 |
| ExternalDocumentID | oai_doaj_org_article_e797b6f4aab84c6e8ee22d247b480f80 A801047439 38992753 10_1186_s13023_024_03245_3 |
| Genre | Journal Article |
| GeographicLocations | United States Europe United Kingdom Spain |
| GeographicLocations_xml | – name: Europe – name: United States – name: United Kingdom – name: Spain |
| GrantInformation_xml | – fundername: Amryt Pharma funderid: http://dx.doi.org/10.13039/100018293 |
| GroupedDBID | --- 0R~ 123 29N 2WC 53G 5VS 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABDBF ABUWG ACGFO ACGFS ACIHN ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AN0 AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BNQBC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EBD EBLON EBS EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR ISR ITC KQ8 M1P M48 MK0 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS UKHRP WOQ WOW ~8M AAYXX AFFHD CITATION ALIPV CGR CUY CVF ECM EIF NPM 7X8 |
| ID | FETCH-LOGICAL-c558t-5eae169b425d34c5bc8f3746c981fdf9aea14f3be6d228634ae76b36f8a38bb3 |
| IEDL.DBID | RSV |
| ISICitedReferencesCount | 3 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001266306600001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1750-1172 |
| IngestDate | Fri Oct 03 12:40:52 EDT 2025 Fri Sep 05 13:03:56 EDT 2025 Sat Nov 29 13:59:54 EST 2025 Sat Nov 29 10:37:43 EST 2025 Wed Nov 26 11:15:15 EST 2025 Thu Apr 03 07:08:12 EDT 2025 Sat Nov 29 03:40:49 EST 2025 Tue Nov 18 19:42:07 EST 2025 Sat Sep 06 07:29:01 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Metreleptin Partial lipodystrophy Physician perspective Patient journey Diagnosis Generalized lipodystrophy Quality of life |
| Language | English |
| License | 2024. The Author(s). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c558t-5eae169b425d34c5bc8f3746c981fdf9aea14f3be6d228634ae76b36f8a38bb3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0002-5926-7784 0000-0003-2852-7851 |
| OpenAccessLink | https://link.springer.com/10.1186/s13023-024-03245-3 |
| PMID | 38992753 |
| PQID | 3079172782 |
| PQPubID | 23479 |
| PageCount | 11 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_e797b6f4aab84c6e8ee22d247b480f80 proquest_miscellaneous_3079172782 gale_infotracmisc_A801047439 gale_infotracacademiconefile_A801047439 gale_incontextgauss_ISR_A801047439 pubmed_primary_38992753 crossref_citationtrail_10_1186_s13023_024_03245_3 crossref_primary_10_1186_s13023_024_03245_3 springer_journals_10_1186_s13023_024_03245_3 |
| PublicationCentury | 2000 |
| PublicationDate | 2024-07-11 |
| PublicationDateYYYYMMDD | 2024-07-11 |
| PublicationDate_xml | – month: 07 year: 2024 text: 2024-07-11 day: 11 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Orphanet journal of rare diseases |
| PublicationTitleAbbrev | Orphanet J Rare Dis |
| PublicationTitleAlternate | Orphanet J Rare Dis |
| PublicationYear | 2024 |
| Publisher | BioMed Central BioMed Central Ltd BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: BMC |
| References | S Grundfest-Broniatowski (3245_CR50) 2017; 21 3245_CR21 3245_CR22 3245_CR23 K Lim (3245_CR13) 2021; 101 A Melvin (3245_CR51) 2017; 102 S Magno (3245_CR9) 2023 EA Oral (3245_CR40) 2002; 346 RJ Brown (3245_CR3) 2016; 101 3245_CR28 T Diker-Cohen (3245_CR47) 2015; 100 3245_CR24 3245_CR25 3245_CR27 A Garg (3245_CR1) 2004; 350 F Corvillo (3245_CR12) 2023; 72 3245_CR52 H Mosbah (3245_CR48) 2022; 24 TE Paterick (3245_CR55) 2017; 30 N Patni (3245_CR5) 2019; 104 A Garg (3245_CR36) 2000; 85 J Zammouri (3245_CR20) 2021; 12 B Akinci (3245_CR19) 2018; 18 LT Fourman (3245_CR29) 2022; 107 C Musso (3245_CR46) 2016; 9 N Gupta (3245_CR10) 2017; 102 RJ Brown (3245_CR54) 2016; 57 3245_CR15 D Araujo-Vilar (3245_CR32) 2015; 49 3245_CR44 SA Martin (3245_CR18) 2022; 6 A Misra (3245_CR8) 2004; 83 RJ Brown (3245_CR42) 2018; 60 E Bellini (3245_CR49) 2017; 24 C Vigouroux (3245_CR37) 2000; 49 JL Chan (3245_CR41) 2011; 17 A Zhong (3245_CR53) 2022; 32 MC Foss-Freitas (3245_CR6) 2020; 15 D Araujo-Vilar (3245_CR14) 2019; 42 N Patni (3245_CR4) 2022; 22 3245_CR34 A Gomes (3245_CR17) 2021; 14 A Stears (3245_CR33) 2014; 9 I Yildirim Simsir (3245_CR31) 2023; 25 J Hwang (3245_CR56) 2023; 32 3245_CR30 EA Oral (3245_CR43) 2019; 64 A Misra (3245_CR7) 2003; 82 E Chiquette (3245_CR2) 2017; 10 N Ajluni (3245_CR16) 2017; 86 B Akinci (3245_CR11) 2018; 18 J Lebastchi (3245_CR45) 2015; 100 S Ozen (3245_CR26) 2020; 12 T Demir (3245_CR39) 2024; 19 3245_CR35 3245_CR38 |
| References_xml | – volume: 10 start-page: 375 year: 2017 ident: 3245_CR2 publication-title: Diabetes Metab Syndr Obes. doi: 10.2147/DMSO.S130810 – year: 2023 ident: 3245_CR9 publication-title: J Clin Endocrinol Metab. doi: 10.1210/clinem/dgad700 – volume: 18 start-page: 139 year: 2018 ident: 3245_CR19 publication-title: Curr Diab Rep. doi: 10.1007/s11892-018-1100-7 – ident: 3245_CR24 – volume: 346 start-page: 570 year: 2002 ident: 3245_CR40 publication-title: N Engl J Med. doi: 10.1056/NEJMoa012437 – volume: 107 start-page: 1714 year: 2022 ident: 3245_CR29 publication-title: J Clin Endocrinol Metab. doi: 10.1210/clinem/dgac079 – ident: 3245_CR28 doi: 10.1210/jc.2018-02730 – ident: 3245_CR34 – volume: 102 start-page: 3616 year: 2017 ident: 3245_CR51 publication-title: J Clin Endocrinol Metab. doi: 10.1210/jc.2017-01235 – volume: 102 start-page: 363 year: 2017 ident: 3245_CR10 publication-title: J Clin Endocrinol Metab. doi: 10.1210/jc.2016-2271 – volume: 83 start-page: 18 year: 2004 ident: 3245_CR8 publication-title: Medicine (Baltimore). doi: 10.1097/01.md.0000111061.69212.59 – ident: 3245_CR38 – volume: 22 start-page: 461 year: 2022 ident: 3245_CR4 publication-title: Curr Diab Rep. doi: 10.1007/s11892-022-01485-w – ident: 3245_CR21 – volume: 101 start-page: 4500 year: 2016 ident: 3245_CR3 publication-title: J Clin Endocrinol Metab. doi: 10.1210/jc.2016-2466 – volume: 64 start-page: 500 year: 2019 ident: 3245_CR43 publication-title: Endocrine. doi: 10.1007/s12020-019-01862-8 – volume: 24 start-page: 53 year: 2017 ident: 3245_CR49 publication-title: Ann Med Surg (Lond). doi: 10.1016/j.amsu.2017.10.024 – volume: 350 start-page: 1220 year: 2004 ident: 3245_CR1 publication-title: N Engl J Med. doi: 10.1056/NEJMra025261 – volume: 57 start-page: 45 year: 2016 ident: 3245_CR54 publication-title: Leuk Lymphoma. doi: 10.3109/10428194.2015.1040015 – ident: 3245_CR23 – volume: 104 start-page: 1099 year: 2019 ident: 3245_CR5 publication-title: J Clin Endocrinol Metab. doi: 10.1210/jc.2018-01922 – volume: 86 start-page: 698 year: 2017 ident: 3245_CR16 publication-title: Clin Endocrinol (Oxf). doi: 10.1111/cen.13311 – ident: 3245_CR35 doi: 10.1371/journal.pone.0197784 – volume: 100 start-page: 3967 year: 2015 ident: 3245_CR45 publication-title: J Clin Endocrinol Metab. doi: 10.1210/jc.2015-2589 – volume: 9 start-page: 235 year: 2014 ident: 3245_CR33 publication-title: Clinical Lipidology. doi: 10.2217/clp.14.13 – ident: 3245_CR27 doi: 10.1016/j.ando.2022.07.674 – ident: 3245_CR15 doi: 10.1210/jc.2007-2521 – volume: 72 start-page: 71 year: 2023 ident: 3245_CR12 publication-title: Diabetes. doi: 10.2337/db21-1086 – volume: 42 start-page: 61 year: 2019 ident: 3245_CR14 publication-title: J Endocrinol Invest. doi: 10.1007/s40618-018-0887-z – volume: 9 start-page: 123 year: 2016 ident: 3245_CR46 publication-title: Clin Med Insights Case Rep. doi: 10.4137/CCRep.S40196 – volume: 49 start-page: 139 year: 2015 ident: 3245_CR32 publication-title: Endocrine. doi: 10.1007/s12020-014-0450-4 – volume: 100 start-page: 1802 year: 2015 ident: 3245_CR47 publication-title: J Clin Endocrinol Metab. doi: 10.1210/jc.2014-4491 – volume: 12 start-page: 17 year: 2020 ident: 3245_CR26 publication-title: J Clin Res Pediatr Endocrinol. doi: 10.4274/jcrpe.galenos.2019.2019.0124 – ident: 3245_CR22 – volume: 6 start-page: 84 year: 2022 ident: 3245_CR18 publication-title: J Patient Rep Outcomes. doi: 10.1186/s41687-022-00486-3 – volume: 19 start-page: 10 year: 2024 ident: 3245_CR39 publication-title: Orphanet J Rare Dis. doi: 10.1186/s13023-023-03004-w – volume: 49 start-page: 1958 year: 2000 ident: 3245_CR37 publication-title: Diabetes. doi: 10.2337/diabetes.49.11.1958 – ident: 3245_CR30 doi: 10.3389/fendo.2023.1250203 – volume: 32 start-page: 4110 year: 2022 ident: 3245_CR53 publication-title: Obes Surg. doi: 10.1007/s11695-022-06329-w – volume: 15 start-page: 95 year: 2020 ident: 3245_CR6 publication-title: Expert Rev Endocrinol Metab. doi: 10.1080/17446651.2020.1735360 – volume: 60 start-page: 479 year: 2018 ident: 3245_CR42 publication-title: Endocrine. doi: 10.1007/s12020-018-1589-1 – volume: 18 start-page: 143 year: 2018 ident: 3245_CR11 publication-title: Curr Diab Rep. doi: 10.1007/s11892-018-1099-9 – volume: 14 start-page: 673 year: 2021 ident: 3245_CR17 publication-title: Patient. doi: 10.1007/s40271-021-00511-5 – volume: 101 start-page: 907 year: 2021 ident: 3245_CR13 publication-title: Physiol Rev. doi: 10.1152/physrev.00032.2020 – volume: 32 start-page: 61 year: 2023 ident: 3245_CR56 publication-title: BMJ Qual Saf. doi: 10.1136/bmjqs-2022-015054 – ident: 3245_CR25 – volume: 85 start-page: 1776 year: 2000 ident: 3245_CR36 publication-title: J Clin Endocrinol Metab. doi: 10.1210/jcem.85.5.6605 – volume: 17 start-page: 922 year: 2011 ident: 3245_CR41 publication-title: Endocr Pract. doi: 10.4158/EP11229.OR – volume: 24 start-page: 1565 year: 2022 ident: 3245_CR48 publication-title: Diabetes Obes Metab. doi: 10.1111/dom.14726 – volume: 82 start-page: 129 year: 2003 ident: 3245_CR7 publication-title: Medicine (Baltimore). doi: 10.1097/00005792-200303000-00007 – volume: 30 start-page: 112 year: 2017 ident: 3245_CR55 publication-title: Proc (Bayl Univ Med Cent). doi: 10.1080/08998280.2017.11929552 – volume: 25 start-page: 1950 year: 2023 ident: 3245_CR31 publication-title: Diabetes Obes Metab. doi: 10.1111/dom.15061 – ident: 3245_CR44 doi: 10.1210/jendso/bvad114.067 – volume: 21 start-page: 739 year: 2017 ident: 3245_CR50 publication-title: J Gastrointest Surg. doi: 10.1007/s11605-016-3300-2 – ident: 3245_CR52 doi: 10.2337/dc16-0236 – volume: 12 year: 2021 ident: 3245_CR20 publication-title: Front Endocrinol (Lausanne). doi: 10.3389/fendo.2021.803189 |
| SSID | ssj0045308 |
| Score | 2.4192908 |
| Snippet | Background
Lipodystrophy syndromes are a heterogeneous group of rare, life-limiting diseases characterized by a selective loss of adipose tissue and severe... Lipodystrophy syndromes are a heterogeneous group of rare, life-limiting diseases characterized by a selective loss of adipose tissue and severe metabolic... Background Lipodystrophy syndromes are a heterogeneous group of rare, life-limiting diseases characterized by a selective loss of adipose tissue and severe... Abstract Background Lipodystrophy syndromes are a heterogeneous group of rare, life-limiting diseases characterized by a selective loss of adipose tissue and... |
| SourceID | doaj proquest gale pubmed crossref springer |
| SourceType | Open Website Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 263 |
| SubjectTerms | Adipose tissues Analysis Beliefs, opinions and attitudes Care and treatment Development and progression Diagnosis Female Generalized lipodystrophy Genetic disorders Health aspects Homeopathy Human Genetics Humans Leptin - analogs & derivatives Leptin - metabolism Leptin - therapeutic use Lipodystrophy Lipodystrophy - diagnosis Lipodystrophy - therapy Male Materia medica and therapeutics Medical care Medical research Medicine Medicine & Public Health Medicine, Experimental Metreleptin Partial lipodystrophy Patient journey Pharmacology/Toxicology Physician perspective Physicians Practice Quality management Quality of Life Surveys Surveys and Questionnaires Therapeutics |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQhRAXxJtAQQYhcaBRN_EjY27lUcGBCkEPvVm2M0YrlWS12UXqv8ePJHRBKheu8USK5z2Z8WdCXqIUzEkwpQzhLRQo4EqFoioNCOmNWxhhebpsojk5gbMz9eXSVV9xJizDA2fGHWKjGis9N8YCdxIBsa7bmjeWw8JDqtZD1jMVU9kHc8EWMB2RAXk4xPZc7FfychEyCFGynTCU0Pr_9smXgtIfXdIUfI5vk1tj1kiP8tfeIdewu0tufB774veIf58n5pbDAZ1Hx6npWvpjHm-hvafny1XfXgybdR-4-4aG5I_Ovzbo6ve5S9p3eTGjrtKkcXhxn5wefzh997Ecb1AonRCwKQUarKSywTBbxp2wDjxruHQKKt96ZdBU3DOLsq1rkIwbbKRl0oNhYC17QPa6vsNHhDJjWMNQqRZbDhZCVhUSE28bxFBxuLog1cRP7UZ08XjJxblOVQZInWWggwx0koFmBXk9v7PK2BpXUr-NYpopIy52ehC0RY_aov-lLQV5EYWsI_JFF0drvpvtMOhP377qI0hQRSFBK8irkcj3YQ_OjCcVAiciWNYO5f4OZTBNt7P8fNIlHZfiPFuH_XbQwbOqmDpCYNzDrGTzxiLiYR2qyIIcTFqnR8cyXMGfx_-DP0_IzTpZSVNW1T7Z26y3-JRcdz83y2H9LNnYLw9yJ-4 priority: 102 providerName: Directory of Open Access Journals |
| Title | Diagnosis, treatment and management of lipodystrophy: the physician perspective on the patient journey |
| URI | https://link.springer.com/article/10.1186/s13023-024-03245-3 https://www.ncbi.nlm.nih.gov/pubmed/38992753 https://www.proquest.com/docview/3079172782 https://doaj.org/article/e797b6f4aab84c6e8ee22d247b480f80 |
| Volume | 19 |
| WOSCitedRecordID | wos001266306600001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: BioMedCentral customDbUrl: eissn: 1750-1172 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0045308 issn: 1750-1172 databaseCode: RBZ dateStart: 20060101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1750-1172 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0045308 issn: 1750-1172 databaseCode: DOA dateStart: 20060101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1750-1172 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0045308 issn: 1750-1172 databaseCode: M~E dateStart: 20060101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1750-1172 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0045308 issn: 1750-1172 databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Health & Medical Collection customDbUrl: eissn: 1750-1172 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0045308 issn: 1750-1172 databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1750-1172 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0045308 issn: 1750-1172 databaseCode: PIMPY dateStart: 20090101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1750-1172 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0045308 issn: 1750-1172 databaseCode: RSV dateStart: 20061201 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZoixCX8qaBsjIIiQONmsSOPeHWQit66Gq1rdBysmzHrlYqyWqzi9R_j-08YAFVgkukxGMpHs_LnvFnhN4alhPNQMbMuTe3QAEdFyZPYwk5s1InMlc0XDbBx2OYzYpJdyis6avd-5RksNRBrYEdNj7F5nOONE5cFJDHZAvtOHcHXh2nF196-0tzkkB_POav_TZcUEDq_9Me_-KQfsuQBsdz-uD_fvkh2u0CTXzUSsYjdMdUj9G98y6V_gTZT22R3bw5wEO1OZZVib8NFTG4tvh6vqjLm2a1rN2EfMAuXsTDbghe_DyqieuqbWyBWnEQUnPzFF2enlx-_Bx3ly7EOs9hFedGmpQVyulySajOlQZLOGXaMdqWtpBGptQSZViZZcAIlYYzRZgFSUAp8gxtV3Vl9hAmUhJOTFGUpqSgwAViLpaxihvjFik6i1DaT4PQHSC5vxfjWoSFCTDR8k84_onAP0Ei9H7os2jhOG6lPvazO1B6KO3woV5eiU4zheEFV8xSKRVQzQwYk2VlRrmikFhIIvTGy4bwYBmVr8a5kuumEWcXU3EEAd3IxXQRetcR2dqNQcvucIPjhMfX2qDc36B02qw3ml_3Iih8ky-Bq0y9boQzxoWPNsEx7nkrm8PAPEhi5haeETroBVF0tqi5hT8v_o38JbqfBVnmcZruo-3Vcm1eobv6-2reLEdoi894eMII7RyfjCfTUdjhcG-Ts_PJ11FQ0x-z6TF0 |
| linkProvider | Springer Nature |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zb9QwELagIMoL9xEoYBASDzQiiR1nwls5qla0K9SuUN8s2xlXK7XJarOL1H-P7RywgCrBazyWkvGcmZnPhLxGkTMjQMXCuTeXoICJS8zTWEEurDKJyjUPl00UkwmcnJRf-6Gwduh2H0qSwVIHtQbxrvUlNl9z5HHiooA8ZlfJNe48lm_kOzr-NthfnrMEhvGYv-5bc0EBqf9Pe_yLQ_qtQhocz-7t_3vlO-RWH2jSnU4y7pIrWN8jNw77Uvp9Yj91TXazdpuO3eZU1RU9HztiaGPp2WzeVBftctG4A3lPXbxIx78hdP5zVJM2dbfYAbXSIKR48YBMdz9PP-7F_aULsclzWMY5KkxFqZ0uV4ybXBuwrODClJDaypYKVcot0yiqLAPBuMJCaCYsKAZas4dko25qfEwoU4oVDMuywoqDBheIuVjG6gLRJSkmi0g6HIM0PSC5vxfjTIbEBITs-Ccd_2Tgn2QReTvumXdwHJdSf_CnO1J6KO3woFmcyl4zJRZloYXlSmngRiAgZlmV8UJzSCwkEXnlZUN6sIzad-OcqlXbyv3jI7kDAd3IxXQRedMT2cZ9g1H9cIPjhMfXWqPcWqN02mzWll8OIij9km-Bq7FZtdIZ49JHm-AY96iTzfHDPEhi5hLPiGwPgih7W9Rewp8n_0b-gmzuTQ8P5MH-5MtTcjMLcl3EabpFNpaLFT4j18335axdPA8K-QOfwi5I |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9QwDI9goImX8c0OBgSExAOr1jZp6vI2GCcm4DSxCe0tSlJnOmm0p2sPaf89SfrBDtAkxGvjSK1jO3Zt_0zIKxQZMwJUJNz15gIUMFGBWRIpyIRVJlaZ5mHYRD6bwelpcXSpiz9Uuw8pya6nwaM0Ve3eorSdioPYa3y6zecfeRQ7jyCL2HVyg_uhQT5eP_422GKesRiGVpm_7lu7jgJq_5-2-dLl9Fu2NFxC09v___p3yFbvgNL9TmLukmtY3SObX_oU-31iD7riu3mzS8cqdKqqkn4fK2Voben5fFGXF027rN1BvaXOj6TjXxK6-NXCSeuqW-wAXGkQXrx4QE6mH07ef4z6YQyRyTJoowwVJqLQTsdLxk2mDViWc2EKSGxpC4Uq4ZZpFGWagmBcYS40ExYUA63ZQ7JR1RVuE8qUYjnDoiix5KDBOWjOx7E6R3TBi0knJBmORJoeqNzPyziXIWABITv-Scc_Gfgn2YS8GfcsOpiOK6nf-ZMeKT3EdnhQL89kr7ES8yLXwnKlNHAjEBDTtEx5rjnEFuIJeenlRHoQjcpX6ZypVdPIw-Ovch8C6pHz9SbkdU9ka_cNRvVND44THndrjXJnjdJpuVlbfjGIo_RLvjSuwnrVSGekC--FgmPco05Oxw_z4ImpC0gnZHcQStnbqOYK_jz-N_LnZPPoYCo_H84-PSG30iDWeZQkO2SjXa7wKblpfrTzZvks6OZPKmc3LA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Diagnosis%2C+treatment+and+management+of+lipodystrophy%3A+the+physician+perspective+on+the+patient+journey&rft.jtitle=Orphanet+journal+of+rare+diseases&rft.au=Patni%2C+Nivedita&rft.au=Chard%2C+Craig&rft.au=Ara%C3%BAjo-Vilar%2C+David&rft.au=Phillips%2C+Helen&rft.date=2024-07-11&rft.issn=1750-1172&rft.eissn=1750-1172&rft.volume=19&rft.issue=1&rft.spage=263&rft_id=info:doi/10.1186%2Fs13023-024-03245-3&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1750-1172&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1750-1172&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1750-1172&client=summon |